Business news

    Botanix Pharmaceuticals (ASX:BOT) $5M placement complete

    Article Image

    Botanix Pharmaceuticals (ASX:BOT) has completed Tranche 2 of the placement to Antares Capital, raising a total of about $5M.

    Botanix says its Share Purchase Plan for eligible shareholders closed on November 23, with applications received for 15,246,240 Shares raising $960,504 before costs.

    It also says the Plan was undertaken to provide the shareholders the opportunity to apply for up to $30,000 of shares at an issue price of $0.063 each.

    Botanix says funds will be used to progress its pipeline of dermatology assets in light of its recent rosacea study, and prepare for FDA approval of its lead product Sofpironium Bromide.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa